Analysts expect Citius Pharmaceuticals Inc (NASDAQ:CTXR) to announce earnings of ($0.06) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Citius Pharmaceuticals’ earnings. Citius Pharmaceuticals posted earnings of ($0.19) per share in the same quarter last year, which would suggest a positive year over year growth rate of 68.4%. The firm is expected to report its next earnings report on Tuesday, August 13th.

On average, analysts expect that Citius Pharmaceuticals will report full-year earnings of ($0.56) per share for the current financial year. For the next financial year, analysts expect that the firm will post earnings of $0.06 per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Citius Pharmaceuticals.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20).

Separately, Zacks Investment Research downgraded shares of Hudson Technologies from a “hold” rating to a “sell” rating in a research note on Monday, April 1st.

Citius Pharmaceuticals stock traded down $0.01 during trading hours on Thursday, reaching $1.02. 70,308 shares of the stock were exchanged, compared to its average volume of 162,353. The company has a market cap of $22.52 million, a P/E ratio of -0.87 and a beta of 0.51. Citius Pharmaceuticals has a twelve month low of $0.86 and a twelve month high of $3.14. The stock has a 50 day moving average price of $1.06.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Featured Article: Producer Price Index (PPI)

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with's FREE daily email newsletter.